Shin Nippon Biomedical Laboratories Ltd
F:YB3
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/FCFE
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Price to Free Cash Flow to Equity (P/FCFE) ratio compares a company`s market value to the free cash flow available to its shareholders. It`s similar to the P/OCF ratio but more precise, since it accounts for capital expenditures deducted from operating cash flow.
Valuation Scenarios
If P/FCFE returns to its 3-Year Average (15.3), the stock would be worth €8.54 (15% upside from current price).
| Scenario | P/FCFE Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.4 | €7.45 |
0%
|
| 3-Year Average | 15.3 | €8.54 |
+15%
|
| 5-Year Average | 15.7 | €8.74 |
+17%
|
| Industry Average | 15.6 | €8.69 |
+17%
|
| Country Average | 22.4 | €12.44 |
+67%
|
Forward P/FCFE
Today’s price vs future free cash flow to equity
Peer Comparison
| Market Cap | P/FCFE | P/E | ||||
|---|---|---|---|---|---|---|
| JP |
S
|
Shin Nippon Biomedical Laboratories Ltd
F:YB3
|
58.7B EUR | 13.4 | 14.7 | |
| US |
P
|
PerkinElmer Inc
LSE:0KHE
|
936.1B USD | 2 167.8 | 3 881 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
178B USD | 12.2 | 25.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
126.6B USD | 19.3 | 33.5 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
82.3T KRW | 190.3 | 46.1 | |
| CN |
|
WuXi AppTec Co Ltd
SSE:603259
|
326.9B CNY | 21.5 | 17.1 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
32.9B CHF | -40.7 | -119.6 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
32.7B USD | 36.5 | 25.1 | |
| US |
|
Waters Corp
NYSE:WAT
|
30.3B USD | 107.3 | 47.1 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
26.9B USD | 9.7 | 19.7 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
26B USD | 31.9 | 29.9 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 14.9 |
| Median | 22.4 |
| 70th Percentile | 35 |
| Max | 736 044 589.7 |
Other Multiples
Shin Nippon Biomedical Laboratories Ltd
Glance View
Shin Nippon Biomedical Laboratories, Ltd. is a contract research organization providing drug development services including safety research, clinical pharmacology, and clinical trials. The company is headquartered in Chuo-Ku, Tokyo-To and currently employs 986 full-time employees. The company went IPO on 2004-03-08. The firm has four business segments. The Preclinical segment is engaged in the verification of the effectiveness and safety of new drugs by conducting tests on experimental animals, cells and bacteria. The Clinical segment is engaged in the verification of the effectiveness and safety of test articles on human. The Translational Research segment is involved in the research and development of pharmaceutical products and related technology, as well as the conduction of preclinical and clinical trials, among others. The Others segment is engaged in information collecting business, the sale of environmental analysis equipment, and the operation of accommodation. As of March 31, 2013, the Company had 27 subsidiaries and one associated company.
